Pientzehuang Pharmaceutical reports revenue decline despite credit upgrade

Zhangzhou Pientzehuang Pharmaceutical reported preliminary H1 2025 results with total operating revenue of 537.85m yuan, down 4.81% year-on-year, and net profit of 144.23m yuan, down 16.22%.

The decline was attributed to increased sales expenses and raw material cost pressures.

Despite the performance dip, Lianhe Credit Rating upgraded the company's long-term corporate credit rating to AAA from AA, citing strong competitive advantages in brand, market position, and product portfolio.